The short version of Chain of custody fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Lyophilization removes water under vacuum from a frozen solution, leaving a porous cake or powder. Formulation excipients such as sugars or polyols can stabilize structure during freezing and drying and can raise the glass transition temperature. Residual moisture in the final product remains a critical variable because even small amounts can support hydrolysis over time. Storage recommendations often specify desiccation, darkness, and low temperature, though exact conditions depend on the peptide and its intended use. Stability studies measure changes under defined conditions rather than predicting absolute shelf life.
Peptides are short chains of amino acids linked by amide bonds. Their stability depends on sequence, length, and the chemical environment. Common degradation routes include hydrolysis of the peptide backbone, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and aggregation through hydrophobic or electrostatic interactions. These processes can alter mass, charge, or biological activity, so storage conditions aim to slow them. The relative importance of each route varies widely among peptides.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Temperature is the most common controlled variable, but its effect is not linear. Lower temperatures reduce most chemical reaction rates, yet freezing can concentrate solutes and create pH shifts in the remaining liquid phase. Repeated freeze-thaw cycles can denature or aggregate some peptides, especially those with hydrophobic segments. For lyophilized powders, desiccation and protection from moisture are often more important than deep freezing. For solutions, the choice between refrigeration and freezing depends on peptide concentration, buffer components, and the intended duration of storage.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
=== Anticonvulsants === Although it was previously withdrawn from the market as an appetite suppressant, fenfluramine was reintroduced as an anticonvulsant for treatment of seizures in certain rare forms of epilepsy like Dravet syndrome and Lennox–Gastaut syndrome. Selective serotonin 5-HT2C receptor agonists, like lorcaserin, bexicaserin, and BMB-101, are also being developed for this use.
== M == Methanobacterium extroquens Micrococcus luteus Moraxella catarrhalis Morganella morganii Mycobacterium Mycobacterium avium Mycobacterium bovis Mycobacterium intracellulare Mycobacterium kansasii Mycobacterium leprae Mycobacterium lepraemurium Mycobacterium marinum Mycobacterium phlei Mycobacterium smegmatis Mycobacterium tuberculosis Mycoplasma Mycoplasma fermentans Mycoplasma genitalium Mycoplasma hominis Mycoplasma penetrans Mycoplasma pneumoniae
Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several non-specific and vague signs and symptoms associated with amyloidosis. These include fatigue, peripheral edema, weight loss, shortness of breath, palpitations, and feeling faint with standing. In AL amyloidosis, specific indicators can include enlargement of the tongue and periorbital purpura. In wild-type ATTR amyloidosis, non-cardiac symptoms include: bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture, small fiber neuropathy, and autonomic dysfunction. There are about 36 different types of amyloidosis, each due to a specific protein misfolding. Within these 36 proteins, 19 are grouped into localized forms, 14 are grouped as systemic forms, and three proteins can identify as either. These proteins can become irregular due to genetic effects, as well as through acquired environmental factors. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and wild-type transthyretin amyloid). Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach. Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause.
==== Etifoxine ==== Etifoxine has similar anxiolytic effects as benzodiazepine drugs, but does not produce the same levels of sedation and ataxia. Further, etifoxine does not affect memory and vigilance, and does not induce rebound anxiety, drug dependence, or withdrawal symptoms.
== Mechanism of action == According to PharmaMar, lurbinectedin inhibits the active transcription of the encoding genes. This has two consequences. It promotes tumor cell death and normalizes the tumor microenvironment. Active transcription is the process by which there are specific signal where information contained in the DNA sequence is transferred to an RNA molecule. This activity depends on the activity of an enzyme called RNA polymerase II. Lurbinectedin inhibits transcription through a very precise mechanism. Firstly, lurbinectedin binds to specific DNA sequences. It is at these precise spots that RNA polymerase II slides down the DNA to produce RNA that is blocked and degraded by lurbinectedin. Lurbinectedin also has important role in tumor microenvironment. The tumor cells act upon macrophages to avoid them from behaving like an activator of the immune system. Macrophages can contribute to tumor growth and progression by promoting tumor cell proliferation and invasion, fostering tumor angiogenesis and suppressing antitumor immune cells.
Sources: en.wikipedia.org
==== Adipose tissue ==== Serotonin also regulates white and brown adipose tissue function, and adipocytes are capable of producing 5-HT separately from the gut. Serotonin increases lipogenesis through HTR2A in white adipose tissue, and suppressed thermogenesis in brown adipose tissue via Htr3.
=== Ischemic myocardium === Edlich helped to quantitate the perfusion of a saphenous vein graft implanted in canine ischemic myocardium using tissue blood flow measurements. When his studies failed to show revascularization of the heart, he suggested that the revascularization of the heart could be improved by a coronary artery bypass graft.
=== Oil and petroleum === In the oil industry, 252Cf is used to find layers of petroleum and water in a well. Instrumentation is lowered into the well, which bombards the formation with high energy neutrons to determine porosity, permeability, and hydrocarbon presence along the length of the borehole.
==== Joint injections ==== Intra-articular injections of steroids, hyaluronic acid, or platelet-rich plasma may be used for pain relief in people with knee osteoarthritis. Local drug delivery by intra-articular injection may be more effective and safer in terms of increased bioavailability, less systemic exposure and reduced adverse events. Several intra-articular medications for symptomatic treatment are available.
Datura arenicola Gentry ex Bye & Luna Datura ceratocaula Ortega Datura discolor Bernh. Datura ferox L. Datura innoxia Mill. Datura kymatocarpa Barclay Datura lanosa A.S.Barclay ex Bye Datura leichhardtii Benth. Datura metel L. Datura pruinosa Greenm. Datura quercifolia Kunth Datura reburra Barclay Datura stramonium L. Datura wrightii Regel Of the above, D. leichhardtii is close enough to D. pruinosa to merit demotion to a subspecies and likewise D. ferox and D. quercifolia are close enough in morphology to merit being subsumed in a single species. Furthermore, the Australian provenance of D. leichhardtii, the Chinese provenance of D. ferox, and the Afro-Asiatic provenance of D. metel have been cast into serious doubt, with the three species being almost certainly post-Columbian introductions to the regions to which they were originally thought native. The case of D. metel is unique in that not only is the plant not a true species at all, but an assemblage of ancient pre-Columbian cultivars created from D. innoxia in the Greater Antilles, but evidence is mounting that it was introduced to the Indian subcontinent no later than the second century CE—whether by natural or human agency is, as yet, unknown—making it one of the most ancient plant introductions (if not the most ancient) from the New World to the Old World (see Columbian Exchange). D. arenicola is a recently discovered species, described first in 2013, of very restricted range, and so distinctive as to have merited the creation for it of the new section Discola [not to be confused with the species name D.
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
Peptide degradation can arise from hydrolysis, oxidation, deamidation, and aggregation. The dominant route depends on the peptide sequence and the storage environment. Temperature, moisture, oxygen, light, and pH all influence the rate.